Free Trial

Pluri (PLUR) Competitors

Pluri logo
$5.51 -0.05 (-0.90%)
Closing price 03:42 PM Eastern
Extended Trading
$5.68 +0.17 (+3.10%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PLUR vs. ACRS, NVCT, NLTX, MOLN, TIL, BIOA, CGEN, ALEC, GALT, and ACOG

Should you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Aclaris Therapeutics (ACRS), Nuvectis Pharma (NVCT), Neoleukin Therapeutics (NLTX), Molecular Partners (MOLN), Instil Bio (TIL), BioAge Labs (BIOA), Compugen (CGEN), Alector (ALEC), Galectin Therapeutics (GALT), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.

Pluri vs. Its Competitors

Pluri (NASDAQ:PLUR) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

Pluri has higher earnings, but lower revenue than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pluri$330K130.74-$20.89M-$5.53-1.00
Aclaris Therapeutics$18.72M8.91-$132.07M-$1.39-1.11

In the previous week, Pluri had 1 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 3 mentions for Pluri and 2 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.77 beat Pluri's score of 0.64 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pluri
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aclaris Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pluri has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the S&P 500.

16.6% of Pluri shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 25.9% of Pluri shares are held by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aclaris Therapeutics has a net margin of -732.42% compared to Pluri's net margin of -2,563.29%. Aclaris Therapeutics' return on equity of -30.73% beat Pluri's return on equity.

Company Net Margins Return on Equity Return on Assets
Pluri-2,563.29% -4,191.91% -85.40%
Aclaris Therapeutics -732.42%-30.73%-22.74%

Pluri presently has a consensus price target of $12.00, indicating a potential upside of 117.79%. Aclaris Therapeutics has a consensus price target of $9.71, indicating a potential upside of 530.80%. Given Aclaris Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than Pluri.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pluri
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Aclaris Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11

Summary

Aclaris Therapeutics beats Pluri on 11 of the 17 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PLUR vs. The Competition

MetricPluriMED IndustryMedical SectorNASDAQ Exchange
Market Cap$43.55M$2.90B$5.50B$8.96B
Dividend YieldN/A2.44%5.25%4.02%
P/E Ratio-1.007.8219.9019.84
Price / Sales130.74295.68436.90127.27
Price / CashN/A41.8337.0657.97
Price / Book5.517.868.125.62
Net Income-$20.89M-$54.95M$3.16B$248.50M
7 Day Performance2.23%6.24%4.40%5.54%
1 Month Performance25.51%5.70%4.09%7.52%
1 Year Performance-5.00%8.08%34.53%22.06%

Pluri Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PLUR
Pluri
3.3433 of 5 stars
$5.51
-0.9%
$12.00
+117.8%
-3.8%$43.55M$330K-1.00150News Coverage
Gap Down
ACRS
Aclaris Therapeutics
2.6211 of 5 stars
$1.42
-3.4%
$9.71
+584.1%
+14.2%$159.17M$18.72M-1.02100
NVCT
Nuvectis Pharma
3.2535 of 5 stars
$7.47
-1.1%
$17.00
+127.6%
+19.0%$157.75MN/A-6.618News Coverage
Positive News
NLTX
Neoleukin Therapeutics
N/A$16.16
-2.5%
N/A-47.0%$151.87MN/A-5.2090High Trading Volume
MOLN
Molecular Partners
2.7956 of 5 stars
$3.79
+0.8%
$12.00
+216.6%
-44.8%$151.81M$5.65M-1.97180
TIL
Instil Bio
3.1138 of 5 stars
$20.83
-9.3%
$119.00
+471.3%
+130.6%$150.66MN/A-1.74410Positive News
BIOA
BioAge Labs
N/A$4.13
-1.7%
N/AN/A$150.57MN/A0.00N/ANews Coverage
CGEN
Compugen
1.5404 of 5 stars
$1.78
+7.2%
$4.00
+124.7%
-0.6%$148.13M$27.86M-11.1370Positive News
ALEC
Alector
4.0507 of 5 stars
$1.40
-5.4%
$4.00
+185.7%
-67.0%$147.99M$100.56M-1.11270News Coverage
GALT
Galectin Therapeutics
1.0999 of 5 stars
$2.11
-9.4%
$6.00
+184.4%
-4.6%$147.47MN/A-2.939Positive News
ACOG
Alpha Cognition
1.698 of 5 stars
$9.33
+2.5%
$20.00
+114.4%
N/A$145.86MN/A-7.77N/A

Related Companies and Tools


This page (NASDAQ:PLUR) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners